SLGL (Sol-Gel Technologies) EBIT: $-2.32 Mil (TTM As of Mar. 2026)

What is Sol-Gel Technologies EBIT?

Sol-Gel Technologies SLGL +3.12% 56 EBIT is $-2.32 Mil as of Mar. 2026. GuruFocus rates SLGL with a GF Score™ of 56/100 and a GF Value™ of $65.37 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Sol-Gel Technologies's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-3.86 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.32 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sol-Gel Technologies's annualized ROC % for the quarter that ended in Mar. 2026 was -461.19%. Sol-Gel Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,399.27%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sol-Gel Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1.22%.

Sol-Gel Technologies (NAS:SLGL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sol-Gel Technologies's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-15.42 * ( 1 - 0% )	/	( (3.441	+	3.246)	/ 2 )
=	-15.42	/	3.3435
=	-461.19 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	29.917	-	5.676	-	( 23.999	-	max(0, 6.171	-	26.971	+	23.999	))
=	3.441

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	58.55	-	5.828	-	( 52.828	-	max(0, 6.313	-	55.789	+	52.828	))
=	3.246

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sol-Gel Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-15.42	/	( ( (1.167 + max(-2.704, 0))	+	(1.037 + max(-2.867, 0)) )	/	2 )
=	-15.42	/	( ( 1.167	+	1.037 )	/	2 )
=	-15.42	/	1.102
=	-1,399.27 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.968	+	0	+	1.004)	-	(5.676	+	0	+	0)
=	-2.704

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.067	+	0	+	1.894)	-	(5.828	+	0	+	-8.8817841970013E-16)
=	-2.867

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sol-Gel Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-2.324	/	191.248
	=	-1.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sol-Gel Technologies EBIT Related Terms

Sol-Gel Technologies EBIT Historical Data

* Premium members only.

The historical data trend for Sol-Gel Technologies's EBIT can be seen below:

Sol-Gel Technologies EBIT Chart

Sol-Gel Technologies Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

2.96

-16.24

-29.31

-12.01

-7.54

Sol-Gel Technologies Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-9.07	11.23	-6.29	-3.41	-3.86

SLGL vs ALEC, LENZ, CNXU: EBIT Comparison

For the Biotechnology subindustry, Sol-Gel Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sol-Gel Technologies EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sol-Gel Technologies's EV-to-EBIT falls into.

Save Embed

56GF Score

Sol-Gel Technologies Ltd SLGL

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sol-Gel Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.32 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-2.32 Mil mean?

Sol-Gel Technologies (SLGL) has a EBIT of $-2.32 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sol-Gel Technologies.

Is Sol-Gel Technologies' EBIT too high?

Sol-Gel Technologies' current EBIT is $-2.32 Mil. Overall, Sol-Gel Technologies has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Sol-Gel Technologies' EBIT compare to ALEC and LENZ?

Sol-Gel Technologies' EBIT of $-2.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sol-Gel Technologies. Sol-Gel Technologies's current EBIT is $-2.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sol-Gel Technologies stock overvalued right now?

Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Modestly Overvalued. The stock's GF Value™ is $65.37, compared to a current price of $74.40 — trading 13.8% above its estimated fair value. The current EBIT is $-2.32 Mil. Sol-Gel Technologies' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current EBIT is $-2.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sol-Gel Technologies (SLGL) Overvalued in 2026?

Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued. The current stock price of $74.40 is trading 13.8% above its estimated GF Value™ of $65.37. GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.

Key valuation signals for SLGL:

EBIT: $-2.32 Mil
GF Value™: $65.37 vs. price of $74.40 (13.8% above fair value)
GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sol-Gel Technologies Business Description

Industry Healthcare Biotechnology

Comparable Companies ALEC LENZ CNXU CHRS OBIO CRBU VYGR WHWK NKTX IKT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 4SG:Germany

Address 7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650

Website https://www.sol-gel.com

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.

56GF Score

Get the complete analysis for SLGL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$74.40

Price

$65.37

GF Value

View SLGL Analysis

See EBIT data for all stocks →